Exelixis says it will evaluate its cancer drug Cabometyx with Opdivo, Bristol's PD-1 immune checkpoint inhibitor.
Jim Cramer goes through his list of lightning round callers, and says it is time for Gilead to make a move.
Jim Cramer explained why he is taking a different stance from many investors, and doesn't think a sell-off is in the cards.
Jim Cramer quickly provides his take on various stocks from fans of the show.
Jim Cramer goes over various stocks in the lightning round.
Jim Cramer rattles off his take on caller favorite stocks, including one that he held on to for too long.
Jim Cramer is only willing to say yes to one high-yield mortgage REIT. This and more, in his take on various caller favorite stocks.
Jim Cramer rattles off his take on caller favorite stocks, including this retail play that prompted Cramer to change his stance.
Jim Cramer gives his take quickly on caller favorite stocks, including this stock that is a great pick for young investors.
Jim Cramer provides his opinion to caller favorite stocks, including this hospitality play that's way oversold.
CNBC Pro highlights the top performing stocks this week and analyzes whether the good times will continue.
“Mad Money” host Jim Cramer is telling you why today's rally surprised him.
Biogen has seen its value quadruple to more than $100 billion on the back of its successful multiple sclerosis drugs. Now it has new ambitions.
GSK expects it can design technology small and smart enough to manipulate our bodies' electrical systems and create new treatments for diseases.
Three small-cap drug firms are consistently the best biotech performers following the start of the American Society of Hematology's annual meeting.
Data released at the European Society of Medical Oncology meeting over the weekend showed much progress in fighting a number of cancers. Here's what investors need to know.
Some of Tuesday's midday movers:
The CNBC RQ 50 identifies companies that don't just spend big on R&D, but spend right, creating return on innovation for shareholders.
It's time for the Lightning Round. Cramer makes the call on viewer favorites.
Shares in biotechs and social media stocks fell Tuesday after a Fed report suggested their valuations appear stretched.